Figures & data
Figure 1. hCD46tg mice were given 0, 500, 2,000 or 5,000 mIU MV-nAb i.v., respectively, one day prior i.m. immunization with 1 × 105 pfu rMV-SIVgag. UV-inactivated virus and mice that did not receive measles nAb prior immunization served as controls. Measles antibody titers were determined by endpoint titration at day one and week 2. Fold increase of the median titers between these two time-points are shown in the different groups.
Figure 2. Humoral response against MV. hCD46tg mice were given 500 mIU MV-nAb one day prior to immunization i.m. (panel A) or i.n. (panel B) with 1 × 105 pfu rMV-SIVgag. Development of MV antibody titers over time is shown as median values in lines. The i.m. boost was performed at week 4 with 1 × 105 pfu rMV-SIVgag. Arrows show the time points of immunization.
Figure 3. Induction of neutralization antibodies against MV in pre-immune hCD46tg mice by an i.m.-i.m or i.n.-i.m. prime-boost scenario. Transgenic mice were given MV-nAb (i.v.) one day prior to immunization with 1 × 105 pfu rMV-SIVgag. The concentration of antibodies are shown on panel (A) i.m.-i.m., and panel (B) i.n.-i.m. The i.m. boost of all mice groups was performed at 4 weeks post the prime. Neutralization anti MV antibodies were determined at week 4 (prior to boost) and 8 (after boost) are shown.
Figure 4. Induction of humoral immune responses against SIVgag. hCD46tg mice were given 0 or 500 mIU MV-nAb prior to i.m. or i.n. immunization with 1 × 105 pfu rMVSIVgag. Samples were collected at 4 weeks post prime i.m. (panel A) or i.n. (panel B) and 4 weeks post i.m. boost with 1 × 105 pfu rMV-SIVgag. The median values are shown as lines.
Figure 5. Cellular immune response against MV and the transgene, SIVgag. hCD46tg mice were given 0 or 500 mIU MV-nAb, one day prior to either i.m. or i.n. immunization with 1 × 105 pfu rMV-SIVgag. ELISPOTs were performed 2 weeks post immunization. Panels A and B represent the intramuscular (i.m.) immunization and the measurement of cellular immune response against MV-N (Panel A) and SIVgag (Panel B). Panels C and D represent the intranasal (i.n.) immunization and the measurement of cellular immune responses against MV-N (Panel C) and SIVgag (Panel D). The lines represent the median values.
